The shares of Synthetic Biologics, Inc (NYSE:SYN) and HCP, Inc. (NYSE:HCP) were among the active stocks of the last trading sessions. Synthetic Biologics, Inc (NYSE:SYN) declined to -2.33% closing at the price of $2.1 whereas the shares of HCP, Inc. (NYSE:HCP) soared 1.83% with the increase of 0.46 points closing at the price of $25.66. Synthetic Biologics, Inc has currently decrease -81.65% in its stock over the period of 6-months while its rival HCP, Inc. added 11.47% in the previous 6-months.
Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.
Returns and Profitability
Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.
The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of Synthetic Biologics, Inc (NYSE:SYN) is 0% while the ROI of HCP, Inc. (NYSE:HCP) is 2.6%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, SYN’s EBITDA Margin is -0.53 whereas HCP’s is 20.27.
Both the profitability ratios suggest that HCP, Inc. (NYSE:HCP) is more suitable investment in terms of profitability and return.
EPS & Surprise Factor
Synthetic Biologics, Inc (NYSE:SYN) reported $-1.05/share EPS for the previous quarter where analysts were predicting an EPS to be $-1.4/share Thus beating the analyst Estimates with a Surprise Factor of 25 Percent. While, HCP, Inc. (NYSE:HCP) reported EPS of $0.19/share in the last quarter. The analysts projected EPS of $0.13/share depicting a Surprise of 46.2 Percent.
Taking a look at Earnings per Share, HCP, Inc. tends to be beating the analyst estimates more than Synthetic Biologics, Inc. so HCP is more profitable than SYN.
Technical Analysis of Synthetic Biologics, Inc & HCP, Inc.
Moving average convergence divergence (MACD) shows that Synthetic Biologics, Inc (NYSE:SYN) is on a PRICE RELATIVITY trend While HCP, Inc. (NYSE:HCP) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the Synthetic Biologics, Inc was in BEARISH territory and HCP, Inc. was in BEARISH territory.
SYN’s current statistics gauge that the stock candle is BULLISH with HIGH volatility. While HCP’s candle is BULLISH with HIGH.
EPS Growth Rate: SYN’s 0% versus HCP’s 2.5%
Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of Synthetic Biologics, Inc (NYSE:SYN) is predicted at 0% while HCP, Inc. (NYSE:HCP) stands at 2.5%. These numbers suggest that HCP is more suitable investment in terms of EPS growth rate.
Financial Risk and Liquidity Concerns
The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of SYN stands at 1.8 while HCP is at 0 whereas the debt ratio of the prior is 0 while the debt ratio of the later is 1.44.
The values of the both ratios suggest that one is more liquid and other investment is more risk free.
While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 1.5 for SYN and 2.6 for HCP which means SYN has Buy rating whereas HCP has Hold rating.
Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for SYN is $106.5 which is 98.03% of its current price while HCP has price target of 27 which is 4.96% of its current price.
Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.
SYN currently has price to earning P/E ratio of 0 whereas HCP has 152.74 while the forward P/E ratio for the prior stands at 6.46 and for the later it depicts the value of 47.78.
The price to Book P/B for SYN is 0, Price to Sale is at 0 and for HCP these ratios stand at 2.34 and 6.56.